Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?
Ludeman
Susan M
SM
Duke Comprehensive Cancer Center, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Gamcsik
Michael P
MP
D000171:Acrolein / Q000627:therapeutic use; D000444:Aldehyde Dehydrogenase / Q000378:metabolism; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004260:DNA Repair; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008956:Models, Chemical; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000627:therapeutic use; D010752:Phosphoramide Mustards / Q000627:therapeutic use; D013237:Stereoisomerism
D018906:Antineoplastic Agents, Alkylating; D010752:Phosphoramide Mustards; C030090:phosphoramide mustard; C027061:isophosphamide mustard; D000171:Acrolein; D003520:Cyclophosphamide; D000444:Aldehyde Dehydrogenase; D019853:O(6)-Methylguanine-DNA Methyltransferase; D007069:Ifosfamide